CDXS
Closed
Codexis Inc
2.4
0.0 (0.00%)
Last Update: 01 Jul 2025 23:22:00
Yesterday: 2.44
Day's Range: 2.39 - 2.505
Send
sign up or login to leave a comment!
When Written:
4.14
Codexis Inc. is a biotechnology company that specializes in the development of enzymes for use in industrial processes. The company was founded in 2002 and is headquartered in Redwood City, California.
Codexis' technology platform allows for the engineering of enzymes to improve their performance, stability, and specificity. The company's enzymes are used in a variety of applications, including the production of biofuels, pharmaceuticals, and food ingredients.
Codexis has partnerships with several large companies, including Merck & Co., Inc. and Shell Oil Company. The company has also received funding from the U.S. Department of Energy and the National Institutes of Health.
In addition to its enzyme development activities, Codexis also has a pharmaceutical development program focused on the discovery and development of novel therapeutics for the treatment of rare genetic disorders.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Codexis' technology platform allows for the engineering of enzymes to improve their performance, stability, and specificity. The company's enzymes are used in a variety of applications, including the production of biofuels, pharmaceuticals, and food ingredients.
Codexis has partnerships with several large companies, including Merck & Co., Inc. and Shell Oil Company. The company has also received funding from the U.S. Department of Energy and the National Institutes of Health.
In addition to its enzyme development activities, Codexis also has a pharmaceutical development program focused on the discovery and development of novel therapeutics for the treatment of rare genetic disorders.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








